JP7353663B2 - Gabaa受容体リガンド - Google Patents

Gabaa受容体リガンド Download PDF

Info

Publication number
JP7353663B2
JP7353663B2 JP2021514324A JP2021514324A JP7353663B2 JP 7353663 B2 JP7353663 B2 JP 7353663B2 JP 2021514324 A JP2021514324 A JP 2021514324A JP 2021514324 A JP2021514324 A JP 2021514324A JP 7353663 B2 JP7353663 B2 JP 7353663B2
Authority
JP
Japan
Prior art keywords
compound
rats
pruritus
treatment
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500445A (ja
JP2022500445A5 (cg-RX-API-DMAC7.html
Inventor
ラーセン,ヤヌス,エス.
アムルッカー,ディパック
ヤコブセン,トーマス,アモス
デュ―リング,ティノ
ニールセン,カリン,サンダガー
Original Assignee
サニオナ エー/エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サニオナ エー/エス filed Critical サニオナ エー/エス
Publication of JP2022500445A publication Critical patent/JP2022500445A/ja
Publication of JP2022500445A5 publication Critical patent/JP2022500445A5/ja
Application granted granted Critical
Publication of JP7353663B2 publication Critical patent/JP7353663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021514324A 2018-09-13 2019-09-13 Gabaa受容体リガンド Active JP7353663B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18194297.0 2018-09-13
EP18194297 2018-09-13
PCT/EP2019/074465 WO2020053377A1 (en) 2018-09-13 2019-09-13 A gabaa receptor ligand

Publications (3)

Publication Number Publication Date
JP2022500445A JP2022500445A (ja) 2022-01-04
JP2022500445A5 JP2022500445A5 (cg-RX-API-DMAC7.html) 2022-10-17
JP7353663B2 true JP7353663B2 (ja) 2023-10-02

Family

ID=63579205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514324A Active JP7353663B2 (ja) 2018-09-13 2019-09-13 Gabaa受容体リガンド

Country Status (24)

Country Link
US (1) US11396510B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849976B1 (cg-RX-API-DMAC7.html)
JP (1) JP7353663B2 (cg-RX-API-DMAC7.html)
KR (1) KR102712565B1 (cg-RX-API-DMAC7.html)
CN (1) CN112714765B (cg-RX-API-DMAC7.html)
AU (1) AU2019338236B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110283A1 (cg-RX-API-DMAC7.html)
DK (1) DK3849976T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190717A1 (cg-RX-API-DMAC7.html)
ES (1) ES2935705T3 (cg-RX-API-DMAC7.html)
FI (1) FI3849976T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230067T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060943T2 (cg-RX-API-DMAC7.html)
IL (1) IL281335B2 (cg-RX-API-DMAC7.html)
LT (1) LT3849976T (cg-RX-API-DMAC7.html)
MX (1) MX2021003010A (cg-RX-API-DMAC7.html)
PH (1) PH12021550299A1 (cg-RX-API-DMAC7.html)
PL (1) PL3849976T3 (cg-RX-API-DMAC7.html)
PT (1) PT3849976T (cg-RX-API-DMAC7.html)
SG (1) SG11202101360VA (cg-RX-API-DMAC7.html)
SI (1) SI3849976T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020053377A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100976B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240197733A1 (en) 2021-04-16 2024-06-20 Saniona A/S A gaba receptor modulator for use in the treatment of pain
EP4777104A1 (en) * 2023-09-15 2026-07-22 Saniona A/S A gaba receptor modulator for treating disorders associated with sleep spindle deficits
EP4777103A1 (en) * 2023-09-15 2026-07-22 Saniona A/S A gaba receptor modulator for use in the treatment of absence seizures
WO2026109691A1 (en) * 2024-11-22 2026-05-28 Saniona A/S A gaba receptor modulator for use in the treatment of tremor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508530A (ja) 1999-09-07 2003-03-04 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとなるイミダゾ−ピリジン誘導体
WO2003087099A1 (en) 2002-04-11 2003-10-23 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
WO2003086406A1 (en) 2002-04-11 2003-10-23 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
JP2005531582A (ja) 2002-05-24 2005-10-20 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとしてのイミダゾ−ピリジン誘導体
JP2009530353A (ja) 2006-03-24 2009-08-27 ノイロサーチ アクティーゼルスカブ ベンズイミダゾール誘導体、及びgabaa受容体複合体をモジュレートするためのその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675484B2 (en) 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
GB9702524D0 (en) 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
JP2002535407A (ja) * 1999-01-27 2002-10-22 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとしてのトリアゾロピリダジン誘導体
MXPA05010449A (es) 2003-04-03 2006-05-31 Neurosearch As Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa.
TW201029986A (en) 2008-11-14 2010-08-16 Neurosearch As Novel compounds
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508530A (ja) 1999-09-07 2003-03-04 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとなるイミダゾ−ピリジン誘導体
WO2003087099A1 (en) 2002-04-11 2003-10-23 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
WO2003086406A1 (en) 2002-04-11 2003-10-23 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
JP2005531582A (ja) 2002-05-24 2005-10-20 メルク シャープ エンド ドーム リミテッド Gaba受容体のリガンドとしてのイミダゾ−ピリジン誘導体
JP2009530353A (ja) 2006-03-24 2009-08-27 ノイロサーチ アクティーゼルスカブ ベンズイミダゾール誘導体、及びgabaa受容体複合体をモジュレートするためのその使用

Also Published As

Publication number Publication date
LT3849976T (lt) 2023-02-10
EP3849976A1 (en) 2021-07-21
PT3849976T (pt) 2023-01-13
US11396510B2 (en) 2022-07-26
HUE060943T2 (hu) 2023-04-28
EA202190717A1 (ru) 2021-09-22
DK3849976T3 (da) 2023-01-23
FI3849976T3 (fi) 2023-02-19
WO2020053377A1 (en) 2020-03-19
CA3110283A1 (en) 2020-03-19
PL3849976T3 (pl) 2023-02-27
IL281335A (en) 2021-04-29
CN112714765A (zh) 2021-04-27
MX2021003010A (es) 2021-05-27
BR112021004661A2 (pt) 2021-06-01
KR102712565B1 (ko) 2024-10-02
CN112714765B (zh) 2023-06-30
SG11202101360VA (en) 2021-03-30
IL281335B1 (en) 2024-03-01
ZA202100976B (en) 2022-08-31
JP2022500445A (ja) 2022-01-04
US20210332042A1 (en) 2021-10-28
HRP20230067T1 (hr) 2023-03-17
PH12021550299A1 (en) 2021-10-25
ES2935705T3 (es) 2023-03-09
IL281335B2 (en) 2024-07-01
AU2019338236B2 (en) 2025-01-09
SI3849976T1 (sl) 2023-03-31
EP3849976B1 (en) 2022-10-26
KR20210061338A (ko) 2021-05-27
AU2019338236A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
De Witt et al. Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors
US12551474B2 (en) Use of pridopidine for the treatment of fragile X syndrome
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
CN112714765B (zh) Gabaa受体配体
JP2020513005A (ja) Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
MX2015004162A (es) Usos novedosos.
AU2014368961A2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020010120A2 (pt) compostos derivados de pirimidina e sua composição farmacêutica
CN107404876A (zh) 抗癌治疗剂
EA042675B1 (ru) Лиганд рецептора гамк-а
HK40057209B (en) A gabaa receptor ligand
HK40057209A (en) A gabaa receptor ligand
Botsula et al. New pharmaceutical materials with analgesic activity based on 1, 2, 3-triazolo-1, 4-benzodiazepine
AU2015363757B2 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
Schwartz S. 27.01 The dopamine D3 receptor as a therapeutic target
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230810

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230912

R150 Certificate of patent or registration of utility model

Ref document number: 7353663

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350